nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—P-Glycoprotein Inhibitors—Cyclosporine—systemic lupus erythematosus	0.315	0.521	CiPCiCtD
Everolimus—Cytochrome P450 3A4 Inhibitors—Cyclosporine—systemic lupus erythematosus	0.289	0.479	CiPCiCtD
Everolimus—FKBP1A—Cyclosporine—systemic lupus erythematosus	0.172	0.747	CbGbCtD
Everolimus—CYP3A4—Methylprednisolone—systemic lupus erythematosus	0.0085	0.0369	CbGbCtD
Everolimus—CYP3A4—Dapsone—systemic lupus erythematosus	0.00743	0.0322	CbGbCtD
Everolimus—CYP3A4—Mycophenolate mofetil—systemic lupus erythematosus	0.00644	0.0279	CbGbCtD
Everolimus—CYP3A4—Triamcinolone—systemic lupus erythematosus	0.00644	0.0279	CbGbCtD
Everolimus—CYP3A4—Betamethasone—systemic lupus erythematosus	0.00553	0.024	CbGbCtD
Everolimus—CYP3A4—Prednisolone—systemic lupus erythematosus	0.00545	0.0237	CbGbCtD
Everolimus—CYP3A4—Hydrocortisone—systemic lupus erythematosus	0.00517	0.0224	CbGbCtD
Everolimus—CYP3A4—Prednisone—systemic lupus erythematosus	0.00515	0.0223	CbGbCtD
Everolimus—CYP3A4—Cyclosporine—systemic lupus erythematosus	0.00488	0.0212	CbGbCtD
Everolimus—CYP3A4—Dexamethasone—systemic lupus erythematosus	0.00322	0.0139	CbGbCtD
Everolimus—MTOR—blood plasma—systemic lupus erythematosus	0.00204	0.0993	CbGeAlD
Everolimus—FKBP1A—blood plasma—systemic lupus erythematosus	0.00183	0.0893	CbGeAlD
Everolimus—CYP3A4—urine—systemic lupus erythematosus	0.00115	0.0559	CbGeAlD
Everolimus—MTOR—connective tissue—systemic lupus erythematosus	0.00109	0.0529	CbGeAlD
Everolimus—MTOR—skin of body—systemic lupus erythematosus	0.00098	0.0477	CbGeAlD
Everolimus—FKBP1A—connective tissue—systemic lupus erythematosus	0.000976	0.0476	CbGeAlD
Everolimus—MTOR—kidney—systemic lupus erythematosus	0.000924	0.045	CbGeAlD
Everolimus—FKBP1A—skin of body—systemic lupus erythematosus	0.000881	0.0429	CbGeAlD
Everolimus—FKBP1A—kidney—systemic lupus erythematosus	0.000831	0.0405	CbGeAlD
Everolimus—FKBP1A—cortex of kidney—systemic lupus erythematosus	0.000809	0.0394	CbGeAlD
Everolimus—MTOR—lymphoid tissue—systemic lupus erythematosus	0.000793	0.0387	CbGeAlD
Everolimus—MTOR—tendon—systemic lupus erythematosus	0.000746	0.0363	CbGeAlD
Everolimus—MTOR—bone marrow—systemic lupus erythematosus	0.000722	0.0352	CbGeAlD
Everolimus—FKBP1A—lymphoid tissue—systemic lupus erythematosus	0.000714	0.0348	CbGeAlD
Everolimus—FKBP1A—tendon—systemic lupus erythematosus	0.000671	0.0327	CbGeAlD
Everolimus—MTOR—lung—systemic lupus erythematosus	0.000655	0.0319	CbGeAlD
Everolimus—FKBP1A—bone marrow—systemic lupus erythematosus	0.00065	0.0317	CbGeAlD
Everolimus—MTOR—nervous system—systemic lupus erythematosus	0.000606	0.0295	CbGeAlD
Everolimus—CYP3A4—blood plasma—systemic lupus erythematosus	0.000599	0.0292	CbGeAlD
Everolimus—FKBP1A—lung—systemic lupus erythematosus	0.000589	0.0287	CbGeAlD
Everolimus—MTOR—central nervous system—systemic lupus erythematosus	0.000584	0.0284	CbGeAlD
Everolimus—FKBP1A—nervous system—systemic lupus erythematosus	0.000545	0.0266	CbGeAlD
Everolimus—FKBP1A—central nervous system—systemic lupus erythematosus	0.000525	0.0256	CbGeAlD
Everolimus—CYP3A4—kidney—systemic lupus erythematosus	0.000271	0.0132	CbGeAlD
Everolimus—CYP3A4—nervous system—systemic lupus erythematosus	0.000178	0.00868	CbGeAlD
Everolimus—CYP3A4—central nervous system—systemic lupus erythematosus	0.000172	0.00836	CbGeAlD
Everolimus—MTOR—Adaptive Immune System—LYN—systemic lupus erythematosus	3.81e-05	0.000843	CbGpPWpGaD
Everolimus—MTOR—Immune System—C4B—systemic lupus erythematosus	3.76e-05	0.000833	CbGpPWpGaD
Everolimus—MTOR—Immune System—C4A—systemic lupus erythematosus	3.76e-05	0.000833	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—CDKN1B—systemic lupus erythematosus	3.75e-05	0.000831	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—MMP9—systemic lupus erythematosus	3.69e-05	0.000817	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—CDKN1A—systemic lupus erythematosus	3.68e-05	0.000814	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—BLK—systemic lupus erythematosus	3.65e-05	0.000807	CbGpPWpGaD
Everolimus—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—systemic lupus erythematosus	3.61e-05	0.000799	CbGpPWpGaD
Everolimus—MTOR—Immune System—TLR7—systemic lupus erythematosus	3.61e-05	0.000798	CbGpPWpGaD
Everolimus—MTOR—Immune System—PDCD1—systemic lupus erythematosus	3.61e-05	0.000798	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—CDKN1B—systemic lupus erythematosus	3.59e-05	0.000793	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—CDKN1B—systemic lupus erythematosus	3.57e-05	0.00079	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—CDKN1B—systemic lupus erythematosus	3.55e-05	0.000786	CbGpPWpGaD
Everolimus—MTOR—Immune System—XRCC6—systemic lupus erythematosus	3.54e-05	0.000783	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—CDKN1B—systemic lupus erythematosus	3.53e-05	0.000782	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—CDKN1A—systemic lupus erythematosus	3.52e-05	0.000779	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—CDKN1B—systemic lupus erythematosus	3.48e-05	0.000771	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—CDKN1A—systemic lupus erythematosus	3.46e-05	0.000767	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—TYK2—systemic lupus erythematosus	3.46e-05	0.000766	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—IL6—systemic lupus erythematosus	3.44e-05	0.000761	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—NAT2—systemic lupus erythematosus	3.42e-05	0.000757	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—NAT2—systemic lupus erythematosus	3.37e-05	0.000747	CbGpPWpGaD
Everolimus—MTOR—Immune System—CR1—systemic lupus erythematosus	3.35e-05	0.000742	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—IL6—systemic lupus erythematosus	3.34e-05	0.00074	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—CDKN1B—systemic lupus erythematosus	3.32e-05	0.000736	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—CDKN1B—systemic lupus erythematosus	3.32e-05	0.000736	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—CDKN1B—systemic lupus erythematosus	3.32e-05	0.000736	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—EP300—systemic lupus erythematosus	3.31e-05	0.000733	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—IL6—systemic lupus erythematosus	3.31e-05	0.000733	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—CDKN1A—systemic lupus erythematosus	3.31e-05	0.000732	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—CDKN1B—systemic lupus erythematosus	3.29e-05	0.000729	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—CDKN1A—systemic lupus erythematosus	3.29e-05	0.000729	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TLR9—systemic lupus erythematosus	3.28e-05	0.000726	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—CDKN1A—systemic lupus erythematosus	3.28e-05	0.000725	CbGpPWpGaD
Everolimus—MTOR—Disease—XRCC6—systemic lupus erythematosus	3.27e-05	0.000723	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—CDKN1B—systemic lupus erythematosus	3.26e-05	0.000723	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—CDKN1A—systemic lupus erythematosus	3.26e-05	0.000722	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PTPRC—systemic lupus erythematosus	3.26e-05	0.000721	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—CDKN1B—systemic lupus erythematosus	3.25e-05	0.000719	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—IL6—systemic lupus erythematosus	3.23e-05	0.000714	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—IL6—systemic lupus erythematosus	3.23e-05	0.000714	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—CDKN1A—systemic lupus erythematosus	3.21e-05	0.000711	CbGpPWpGaD
Everolimus—MTOR—Immune System—TLR6—systemic lupus erythematosus	3.2e-05	0.000708	CbGpPWpGaD
Everolimus—MTOR—Immune System—CFB—systemic lupus erythematosus	3.2e-05	0.000708	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—P2RY12—systemic lupus erythematosus	3.18e-05	0.000703	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—CD80—systemic lupus erythematosus	3.15e-05	0.000698	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—VEGFA—systemic lupus erythematosus	3.14e-05	0.000695	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—HMGB1—systemic lupus erythematosus	3.11e-05	0.000688	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—CDKN1B—systemic lupus erythematosus	3.08e-05	0.000681	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—CDKN1A—systemic lupus erythematosus	3.07e-05	0.000679	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—CDKN1A—systemic lupus erythematosus	3.07e-05	0.000679	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—CDKN1A—systemic lupus erythematosus	3.07e-05	0.000679	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IFNA1—systemic lupus erythematosus	3.06e-05	0.000676	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—CDKN1A—systemic lupus erythematosus	3.04e-05	0.000673	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD40—systemic lupus erythematosus	3.03e-05	0.000671	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—CDKN1A—systemic lupus erythematosus	3.01e-05	0.000667	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—CDKN1A—systemic lupus erythematosus	3e-05	0.000664	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HIST2H2AC—systemic lupus erythematosus	3e-05	0.000664	CbGpPWpGaD
Everolimus—FKBP1A—Disease—JUNB—systemic lupus erythematosus	2.99e-05	0.000663	CbGpPWpGaD
Everolimus—MTOR—Immune System—FCGR3A—systemic lupus erythematosus	2.99e-05	0.000662	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CTLA4—systemic lupus erythematosus	2.99e-05	0.000661	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—RASGRP1—systemic lupus erythematosus	2.98e-05	0.000659	CbGpPWpGaD
Everolimus—MTOR—Immune System—RIPK1—systemic lupus erythematosus	2.95e-05	0.000654	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—CDKN1B—systemic lupus erythematosus	2.94e-05	0.000651	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CSK—systemic lupus erythematosus	2.92e-05	0.000647	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IL6—systemic lupus erythematosus	2.9e-05	0.000642	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—systemic lupus erythematosus	2.86e-05	0.000633	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—RASGRP1—systemic lupus erythematosus	2.86e-05	0.000632	CbGpPWpGaD
Everolimus—MTOR—Immune System—TLR9—systemic lupus erythematosus	2.85e-05	0.000631	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD79A—systemic lupus erythematosus	2.85e-05	0.00063	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—CDKN1A—systemic lupus erythematosus	2.84e-05	0.000628	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PRL—systemic lupus erythematosus	2.76e-05	0.000611	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—CDKN1A—systemic lupus erythematosus	2.72e-05	0.000601	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—IL6—systemic lupus erythematosus	2.7e-05	0.000597	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—IL6—systemic lupus erythematosus	2.68e-05	0.000593	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NCF2—systemic lupus erythematosus	2.67e-05	0.000592	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—TYK2—systemic lupus erythematosus	2.66e-05	0.000589	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—LYN—systemic lupus erythematosus	2.66e-05	0.000588	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HLA-DQA1—systemic lupus erythematosus	2.63e-05	0.000582	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SH2B3—systemic lupus erythematosus	2.6e-05	0.000576	CbGpPWpGaD
Everolimus—MTOR—Immune System—CSK—systemic lupus erythematosus	2.54e-05	0.000563	CbGpPWpGaD
Everolimus—MTOR—Immune System—MBL2—systemic lupus erythematosus	2.52e-05	0.000558	CbGpPWpGaD
Everolimus—Hypotension—Methylprednisolone—systemic lupus erythematosus	2.51e-05	0.000251	CcSEcCtD
Everolimus—MTOR—Immune System—IRF5—systemic lupus erythematosus	2.5e-05	0.000553	CbGpPWpGaD
Everolimus—Pain—Prednisolone—systemic lupus erythematosus	2.5e-05	0.00025	CcSEcCtD
Everolimus—Hepatitis—Methotrexate—systemic lupus erythematosus	2.5e-05	0.00025	CcSEcCtD
Everolimus—Haemorrhage—Methotrexate—systemic lupus erythematosus	2.5e-05	0.00025	CcSEcCtD
Everolimus—Decreased appetite—Hydrocortisone—systemic lupus erythematosus	2.48e-05	0.000249	CcSEcCtD
Everolimus—Pharyngitis—Methotrexate—systemic lupus erythematosus	2.48e-05	0.000248	CcSEcCtD
Everolimus—Abdominal pain—Mycophenolate mofetil—systemic lupus erythematosus	2.48e-05	0.000248	CcSEcCtD
Everolimus—Body temperature increased—Mycophenolate mofetil—systemic lupus erythematosus	2.48e-05	0.000248	CcSEcCtD
Everolimus—Nausea—Leflunomide—systemic lupus erythematosus	2.47e-05	0.000248	CcSEcCtD
Everolimus—Urinary tract disorder—Methotrexate—systemic lupus erythematosus	2.47e-05	0.000247	CcSEcCtD
Everolimus—Gastrointestinal disorder—Hydrocortisone—systemic lupus erythematosus	2.46e-05	0.000247	CcSEcCtD
Everolimus—Fatigue—Hydrocortisone—systemic lupus erythematosus	2.46e-05	0.000247	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—HLA-DQB1—systemic lupus erythematosus	2.46e-05	0.000544	CbGpPWpGaD
Everolimus—Vision blurred—Prednisone—systemic lupus erythematosus	2.45e-05	0.000246	CcSEcCtD
Everolimus—Urethral disorder—Methotrexate—systemic lupus erythematosus	2.45e-05	0.000245	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Triamcinolone—systemic lupus erythematosus	2.45e-05	0.000245	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Methylprednisolone—systemic lupus erythematosus	2.44e-05	0.000245	CcSEcCtD
Everolimus—Pain—Hydrocortisone—systemic lupus erythematosus	2.44e-05	0.000245	CcSEcCtD
Everolimus—Oedema—Dexamethasone—systemic lupus erythematosus	2.44e-05	0.000244	CcSEcCtD
Everolimus—Oedema—Betamethasone—systemic lupus erythematosus	2.44e-05	0.000244	CcSEcCtD
Everolimus—Insomnia—Triamcinolone—systemic lupus erythematosus	2.43e-05	0.000244	CcSEcCtD
Everolimus—Insomnia—Methylprednisolone—systemic lupus erythematosus	2.43e-05	0.000243	CcSEcCtD
Everolimus—Infection—Dexamethasone—systemic lupus erythematosus	2.42e-05	0.000243	CcSEcCtD
Everolimus—Infection—Betamethasone—systemic lupus erythematosus	2.42e-05	0.000243	CcSEcCtD
Everolimus—Ill-defined disorder—Prednisone—systemic lupus erythematosus	2.42e-05	0.000242	CcSEcCtD
Everolimus—Paraesthesia—Triamcinolone—systemic lupus erythematosus	2.41e-05	0.000242	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—CDKN1B—systemic lupus erythematosus	2.41e-05	0.000534	CbGpPWpGaD
Everolimus—Feeling abnormal—Prednisolone—systemic lupus erythematosus	2.41e-05	0.000241	CcSEcCtD
Everolimus—Paraesthesia—Methylprednisolone—systemic lupus erythematosus	2.41e-05	0.000241	CcSEcCtD
Everolimus—MTOR—Disease—HIST2H2AC—systemic lupus erythematosus	2.41e-05	0.000533	CbGpPWpGaD
Everolimus—Anaemia—Prednisone—systemic lupus erythematosus	2.41e-05	0.000241	CcSEcCtD
Everolimus—Shock—Dexamethasone—systemic lupus erythematosus	2.4e-05	0.00024	CcSEcCtD
Everolimus—Shock—Betamethasone—systemic lupus erythematosus	2.4e-05	0.00024	CcSEcCtD
Everolimus—Dyspnoea—Triamcinolone—systemic lupus erythematosus	2.4e-05	0.00024	CcSEcCtD
Everolimus—Nervous system disorder—Betamethasone—systemic lupus erythematosus	2.39e-05	0.00024	CcSEcCtD
Everolimus—Nervous system disorder—Dexamethasone—systemic lupus erythematosus	2.39e-05	0.00024	CcSEcCtD
Everolimus—Agitation—Prednisone—systemic lupus erythematosus	2.39e-05	0.00024	CcSEcCtD
Everolimus—MTOR—Immune System—IFIH1—systemic lupus erythematosus	2.39e-05	0.000529	CbGpPWpGaD
Everolimus—MTOR—Immune System—IRF8—systemic lupus erythematosus	2.39e-05	0.000529	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD247—systemic lupus erythematosus	2.39e-05	0.000529	CbGpPWpGaD
Everolimus—MTOR—Immune System—ITGAM—systemic lupus erythematosus	2.39e-05	0.000529	CbGpPWpGaD
Everolimus—Thrombocytopenia—Dexamethasone—systemic lupus erythematosus	2.39e-05	0.000239	CcSEcCtD
Everolimus—Thrombocytopenia—Betamethasone—systemic lupus erythematosus	2.39e-05	0.000239	CcSEcCtD
Everolimus—Tachycardia—Dexamethasone—systemic lupus erythematosus	2.38e-05	0.000239	CcSEcCtD
Everolimus—Tachycardia—Betamethasone—systemic lupus erythematosus	2.38e-05	0.000239	CcSEcCtD
Everolimus—Angioedema—Prednisone—systemic lupus erythematosus	2.38e-05	0.000238	CcSEcCtD
Everolimus—Hypersensitivity—Cyclosporine—systemic lupus erythematosus	2.37e-05	0.000237	CcSEcCtD
Everolimus—Dyspepsia—Triamcinolone—systemic lupus erythematosus	2.37e-05	0.000237	CcSEcCtD
Everolimus—Dyspepsia—Methylprednisolone—systemic lupus erythematosus	2.36e-05	0.000237	CcSEcCtD
Everolimus—Hyperhidrosis—Betamethasone—systemic lupus erythematosus	2.36e-05	0.000236	CcSEcCtD
Everolimus—Hyperhidrosis—Dexamethasone—systemic lupus erythematosus	2.36e-05	0.000236	CcSEcCtD
Everolimus—Feeling abnormal—Hydrocortisone—systemic lupus erythematosus	2.35e-05	0.000236	CcSEcCtD
Everolimus—Malaise—Prednisone—systemic lupus erythematosus	2.35e-05	0.000235	CcSEcCtD
Everolimus—MTOR—Disease—CSK—systemic lupus erythematosus	2.35e-05	0.000519	CbGpPWpGaD
Everolimus—Eye disorder—Methotrexate—systemic lupus erythematosus	2.34e-05	0.000234	CcSEcCtD
Everolimus—Gastrointestinal pain—Hydrocortisone—systemic lupus erythematosus	2.33e-05	0.000234	CcSEcCtD
Everolimus—Syncope—Prednisone—systemic lupus erythematosus	2.33e-05	0.000234	CcSEcCtD
Everolimus—Anorexia—Betamethasone—systemic lupus erythematosus	2.33e-05	0.000233	CcSEcCtD
Everolimus—Anorexia—Dexamethasone—systemic lupus erythematosus	2.33e-05	0.000233	CcSEcCtD
Everolimus—MTOR—Immune System—NCF2—systemic lupus erythematosus	2.32e-05	0.000515	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD40LG—systemic lupus erythematosus	2.32e-05	0.000514	CbGpPWpGaD
Everolimus—Cardiac disorder—Methotrexate—systemic lupus erythematosus	2.32e-05	0.000232	CcSEcCtD
Everolimus—Fatigue—Triamcinolone—systemic lupus erythematosus	2.32e-05	0.000232	CcSEcCtD
Everolimus—Fatigue—Methylprednisolone—systemic lupus erythematosus	2.31e-05	0.000232	CcSEcCtD
Everolimus—MTOR—Immune System—LYN—systemic lupus erythematosus	2.31e-05	0.000511	CbGpPWpGaD
Everolimus—Hypersensitivity—Mycophenolate mofetil—systemic lupus erythematosus	2.31e-05	0.000231	CcSEcCtD
Everolimus—MTOR—Innate Immune System—JAK1—systemic lupus erythematosus	2.31e-05	0.000511	CbGpPWpGaD
Everolimus—Asthenia—Cyclosporine—systemic lupus erythematosus	2.3e-05	0.000231	CcSEcCtD
Everolimus—Pain—Triamcinolone—systemic lupus erythematosus	2.3e-05	0.00023	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—CD8A—systemic lupus erythematosus	2.3e-05	0.000508	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—IL6—systemic lupus erythematosus	2.29e-05	0.000508	CbGpPWpGaD
Everolimus—Loss of consciousness—Prednisone—systemic lupus erythematosus	2.29e-05	0.000229	CcSEcCtD
Everolimus—MTOR—Immune System—FCGR2A—systemic lupus erythematosus	2.28e-05	0.000505	CbGpPWpGaD
Everolimus—Hypotension—Dexamethasone—systemic lupus erythematosus	2.28e-05	0.000228	CcSEcCtD
Everolimus—Hypotension—Betamethasone—systemic lupus erythematosus	2.28e-05	0.000228	CcSEcCtD
Everolimus—Pruritus—Cyclosporine—systemic lupus erythematosus	2.27e-05	0.000228	CcSEcCtD
Everolimus—Angiopathy—Methotrexate—systemic lupus erythematosus	2.27e-05	0.000227	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—CDKN1B—systemic lupus erythematosus	2.26e-05	0.000501	CbGpPWpGaD
Everolimus—Immune system disorder—Methotrexate—systemic lupus erythematosus	2.26e-05	0.000226	CcSEcCtD
Everolimus—Abdominal pain—Hydrocortisone—systemic lupus erythematosus	2.26e-05	0.000226	CcSEcCtD
Everolimus—Body temperature increased—Hydrocortisone—systemic lupus erythematosus	2.26e-05	0.000226	CcSEcCtD
Everolimus—Convulsion—Prednisone—systemic lupus erythematosus	2.26e-05	0.000226	CcSEcCtD
Everolimus—Mediastinal disorder—Methotrexate—systemic lupus erythematosus	2.25e-05	0.000226	CcSEcCtD
Everolimus—Asthenia—Mycophenolate mofetil—systemic lupus erythematosus	2.25e-05	0.000225	CcSEcCtD
Everolimus—Hypertension—Prednisone—systemic lupus erythematosus	2.25e-05	0.000225	CcSEcCtD
Everolimus—Chills—Methotrexate—systemic lupus erythematosus	2.24e-05	0.000225	CcSEcCtD
Everolimus—MTOR—Immune System—TNFAIP3—systemic lupus erythematosus	2.24e-05	0.000495	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—CDKN1A—systemic lupus erythematosus	2.23e-05	0.000493	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Dexamethasone—systemic lupus erythematosus	2.22e-05	0.000223	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Betamethasone—systemic lupus erythematosus	2.22e-05	0.000223	CcSEcCtD
Everolimus—Pruritus—Mycophenolate mofetil—systemic lupus erythematosus	2.22e-05	0.000222	CcSEcCtD
Everolimus—Arthralgia—Prednisone—systemic lupus erythematosus	2.22e-05	0.000222	CcSEcCtD
Everolimus—Myalgia—Prednisone—systemic lupus erythematosus	2.22e-05	0.000222	CcSEcCtD
Everolimus—Feeling abnormal—Triamcinolone—systemic lupus erythematosus	2.22e-05	0.000222	CcSEcCtD
Everolimus—MTOR—Immune System—BLK—systemic lupus erythematosus	2.21e-05	0.000489	CbGpPWpGaD
Everolimus—Feeling abnormal—Methylprednisolone—systemic lupus erythematosus	2.21e-05	0.000221	CcSEcCtD
Everolimus—Anxiety—Prednisone—systemic lupus erythematosus	2.21e-05	0.000221	CcSEcCtD
Everolimus—Alopecia—Methotrexate—systemic lupus erythematosus	2.21e-05	0.000221	CcSEcCtD
Everolimus—FKBP1A—Disease—JAK1—systemic lupus erythematosus	2.21e-05	0.000488	CbGpPWpGaD
Everolimus—MTOR—Disease—CD247—systemic lupus erythematosus	2.21e-05	0.000488	CbGpPWpGaD
Everolimus—Insomnia—Betamethasone—systemic lupus erythematosus	2.21e-05	0.000221	CcSEcCtD
Everolimus—Insomnia—Dexamethasone—systemic lupus erythematosus	2.21e-05	0.000221	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic lupus erythematosus	2.2e-05	0.00022	CcSEcCtD
Everolimus—Diarrhoea—Cyclosporine—systemic lupus erythematosus	2.2e-05	0.00022	CcSEcCtD
Everolimus—MTOR—Downstream signaling of activated FGFR—IL6—systemic lupus erythematosus	2.19e-05	0.000486	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Methylprednisolone—systemic lupus erythematosus	2.19e-05	0.00022	CcSEcCtD
Everolimus—Paraesthesia—Betamethasone—systemic lupus erythematosus	2.19e-05	0.000219	CcSEcCtD
Everolimus—Paraesthesia—Dexamethasone—systemic lupus erythematosus	2.19e-05	0.000219	CcSEcCtD
Everolimus—Discomfort—Prednisone—systemic lupus erythematosus	2.19e-05	0.000219	CcSEcCtD
Everolimus—Mental disorder—Methotrexate—systemic lupus erythematosus	2.19e-05	0.000219	CcSEcCtD
Everolimus—Malnutrition—Methotrexate—systemic lupus erythematosus	2.18e-05	0.000218	CcSEcCtD
Everolimus—Erythema—Methotrexate—systemic lupus erythematosus	2.18e-05	0.000218	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—IL6—systemic lupus erythematosus	2.16e-05	0.000478	CbGpPWpGaD
Everolimus—Hypersensitivity—Prednisolone—systemic lupus erythematosus	2.15e-05	0.000216	CcSEcCtD
Everolimus—Dyspepsia—Betamethasone—systemic lupus erythematosus	2.15e-05	0.000215	CcSEcCtD
Everolimus—Dyspepsia—Dexamethasone—systemic lupus erythematosus	2.15e-05	0.000215	CcSEcCtD
Everolimus—MTOR—Disease—NCF2—systemic lupus erythematosus	2.15e-05	0.000475	CbGpPWpGaD
Everolimus—Diarrhoea—Mycophenolate mofetil—systemic lupus erythematosus	2.14e-05	0.000215	CcSEcCtD
Everolimus—MTOR—Innate Immune System—C3—systemic lupus erythematosus	2.14e-05	0.000473	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CXCL12—systemic lupus erythematosus	2.14e-05	0.000473	CbGpPWpGaD
Everolimus—Dysgeusia—Methotrexate—systemic lupus erythematosus	2.13e-05	0.000213	CcSEcCtD
Everolimus—Body temperature increased—Triamcinolone—systemic lupus erythematosus	2.13e-05	0.000213	CcSEcCtD
Everolimus—Dizziness—Cyclosporine—systemic lupus erythematosus	2.12e-05	0.000213	CcSEcCtD
Everolimus—Oedema—Prednisone—systemic lupus erythematosus	2.12e-05	0.000213	CcSEcCtD
Everolimus—Abdominal pain—Methylprednisolone—systemic lupus erythematosus	2.12e-05	0.000212	CcSEcCtD
Everolimus—Decreased appetite—Betamethasone—systemic lupus erythematosus	2.12e-05	0.000212	CcSEcCtD
Everolimus—Decreased appetite—Dexamethasone—systemic lupus erythematosus	2.12e-05	0.000212	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—EP300—systemic lupus erythematosus	2.12e-05	0.000469	CbGpPWpGaD
Everolimus—Infection—Prednisone—systemic lupus erythematosus	2.11e-05	0.000211	CcSEcCtD
Everolimus—Gastrointestinal disorder—Dexamethasone—systemic lupus erythematosus	2.11e-05	0.000211	CcSEcCtD
Everolimus—Gastrointestinal disorder—Betamethasone—systemic lupus erythematosus	2.11e-05	0.000211	CcSEcCtD
Everolimus—Back pain—Methotrexate—systemic lupus erythematosus	2.1e-05	0.000211	CcSEcCtD
Everolimus—Hypersensitivity—Hydrocortisone—systemic lupus erythematosus	2.1e-05	0.000211	CcSEcCtD
Everolimus—Fatigue—Dexamethasone—systemic lupus erythematosus	2.1e-05	0.000211	CcSEcCtD
Everolimus—Fatigue—Betamethasone—systemic lupus erythematosus	2.1e-05	0.000211	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—JUNB—systemic lupus erythematosus	2.1e-05	0.000464	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CCR5—systemic lupus erythematosus	2.09e-05	0.000463	CbGpPWpGaD
Everolimus—Shock—Prednisone—systemic lupus erythematosus	2.09e-05	0.000209	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—CDKN1A—systemic lupus erythematosus	2.09e-05	0.000462	CbGpPWpGaD
Everolimus—Pain—Betamethasone—systemic lupus erythematosus	2.09e-05	0.000209	CcSEcCtD
Everolimus—Pain—Dexamethasone—systemic lupus erythematosus	2.09e-05	0.000209	CcSEcCtD
Everolimus—Nervous system disorder—Prednisone—systemic lupus erythematosus	2.08e-05	0.000209	CcSEcCtD
Everolimus—Tachycardia—Prednisone—systemic lupus erythematosus	2.07e-05	0.000208	CcSEcCtD
Everolimus—Dizziness—Mycophenolate mofetil—systemic lupus erythematosus	2.07e-05	0.000208	CcSEcCtD
Everolimus—Skin disorder—Prednisone—systemic lupus erythematosus	2.06e-05	0.000207	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—IL6—systemic lupus erythematosus	2.06e-05	0.000456	CbGpPWpGaD
Everolimus—Hyperhidrosis—Prednisone—systemic lupus erythematosus	2.05e-05	0.000206	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—C3—systemic lupus erythematosus	2.05e-05	0.000454	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—IL6—systemic lupus erythematosus	2.05e-05	0.000454	CbGpPWpGaD
Everolimus—Vision blurred—Methotrexate—systemic lupus erythematosus	2.05e-05	0.000205	CcSEcCtD
Everolimus—Asthenia—Hydrocortisone—systemic lupus erythematosus	2.05e-05	0.000205	CcSEcCtD
Everolimus—Vomiting—Cyclosporine—systemic lupus erythematosus	2.04e-05	0.000205	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—IL6—systemic lupus erythematosus	2.04e-05	0.000452	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CRP—systemic lupus erythematosus	2.03e-05	0.00045	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—IL6—systemic lupus erythematosus	2.03e-05	0.00045	CbGpPWpGaD
Everolimus—Rash—Cyclosporine—systemic lupus erythematosus	2.03e-05	0.000203	CcSEcCtD
Everolimus—Anorexia—Prednisone—systemic lupus erythematosus	2.02e-05	0.000203	CcSEcCtD
Everolimus—Dermatitis—Cyclosporine—systemic lupus erythematosus	2.02e-05	0.000203	CcSEcCtD
Everolimus—Pruritus—Hydrocortisone—systemic lupus erythematosus	2.02e-05	0.000202	CcSEcCtD
Everolimus—Ill-defined disorder—Methotrexate—systemic lupus erythematosus	2.02e-05	0.000202	CcSEcCtD
Everolimus—Headache—Cyclosporine—systemic lupus erythematosus	2.01e-05	0.000202	CcSEcCtD
Everolimus—Anaemia—Methotrexate—systemic lupus erythematosus	2.01e-05	0.000201	CcSEcCtD
Everolimus—Feeling abnormal—Dexamethasone—systemic lupus erythematosus	2.01e-05	0.000201	CcSEcCtD
Everolimus—Feeling abnormal—Betamethasone—systemic lupus erythematosus	2.01e-05	0.000201	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—VEGFA—systemic lupus erythematosus	2.01e-05	0.000444	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Betamethasone—systemic lupus erythematosus	1.99e-05	0.0002	CcSEcCtD
Everolimus—Gastrointestinal pain—Dexamethasone—systemic lupus erythematosus	1.99e-05	0.0002	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—RASGRP1—systemic lupus erythematosus	1.99e-05	0.000441	CbGpPWpGaD
Everolimus—Vomiting—Mycophenolate mofetil—systemic lupus erythematosus	1.99e-05	0.0002	CcSEcCtD
Everolimus—Hypersensitivity—Triamcinolone—systemic lupus erythematosus	1.98e-05	0.000198	CcSEcCtD
Everolimus—MTOR—Immune System—PTPRC—systemic lupus erythematosus	1.98e-05	0.000438	CbGpPWpGaD
Everolimus—Hypersensitivity—Methylprednisolone—systemic lupus erythematosus	1.98e-05	0.000198	CcSEcCtD
Everolimus—Rash—Mycophenolate mofetil—systemic lupus erythematosus	1.98e-05	0.000198	CcSEcCtD
Everolimus—Dermatitis—Mycophenolate mofetil—systemic lupus erythematosus	1.97e-05	0.000198	CcSEcCtD
Everolimus—MTOR—Immune System—IL1RN—systemic lupus erythematosus	1.97e-05	0.000436	CbGpPWpGaD
Everolimus—Headache—Mycophenolate mofetil—systemic lupus erythematosus	1.96e-05	0.000197	CcSEcCtD
Everolimus—Malaise—Methotrexate—systemic lupus erythematosus	1.96e-05	0.000197	CcSEcCtD
Everolimus—Diarrhoea—Hydrocortisone—systemic lupus erythematosus	1.95e-05	0.000196	CcSEcCtD
Everolimus—MTOR—Innate Immune System—TLR4—systemic lupus erythematosus	1.95e-05	0.000431	CbGpPWpGaD
Everolimus—Leukopenia—Methotrexate—systemic lupus erythematosus	1.95e-05	0.000195	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Prednisone—systemic lupus erythematosus	1.94e-05	0.000194	CcSEcCtD
Everolimus—Dizziness—Prednisolone—systemic lupus erythematosus	1.93e-05	0.000194	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—PRL—systemic lupus erythematosus	1.93e-05	0.000428	CbGpPWpGaD
Everolimus—Asthenia—Triamcinolone—systemic lupus erythematosus	1.93e-05	0.000193	CcSEcCtD
Everolimus—Body temperature increased—Betamethasone—systemic lupus erythematosus	1.93e-05	0.000193	CcSEcCtD
Everolimus—Body temperature increased—Dexamethasone—systemic lupus erythematosus	1.93e-05	0.000193	CcSEcCtD
Everolimus—Abdominal pain—Betamethasone—systemic lupus erythematosus	1.93e-05	0.000193	CcSEcCtD
Everolimus—Abdominal pain—Dexamethasone—systemic lupus erythematosus	1.93e-05	0.000193	CcSEcCtD
Everolimus—Asthenia—Methylprednisolone—systemic lupus erythematosus	1.92e-05	0.000193	CcSEcCtD
Everolimus—Insomnia—Prednisone—systemic lupus erythematosus	1.92e-05	0.000192	CcSEcCtD
Everolimus—CYP3A4—Biological oxidations—RXRA—systemic lupus erythematosus	1.92e-05	0.000424	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—IL6—systemic lupus erythematosus	1.91e-05	0.000423	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—systemic lupus erythematosus	1.91e-05	0.000423	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—IL6—systemic lupus erythematosus	1.91e-05	0.000423	CbGpPWpGaD
Everolimus—Nausea—Cyclosporine—systemic lupus erythematosus	1.91e-05	0.000191	CcSEcCtD
Everolimus—Paraesthesia—Prednisone—systemic lupus erythematosus	1.91e-05	0.000191	CcSEcCtD
Everolimus—Pruritus—Triamcinolone—systemic lupus erythematosus	1.9e-05	0.000191	CcSEcCtD
Everolimus—Cough—Methotrexate—systemic lupus erythematosus	1.9e-05	0.00019	CcSEcCtD
Everolimus—Pruritus—Methylprednisolone—systemic lupus erythematosus	1.9e-05	0.00019	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—IL6—systemic lupus erythematosus	1.89e-05	0.000419	CbGpPWpGaD
Everolimus—Dizziness—Hydrocortisone—systemic lupus erythematosus	1.89e-05	0.000189	CcSEcCtD
Everolimus—Convulsion—Methotrexate—systemic lupus erythematosus	1.88e-05	0.000189	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—IL6—systemic lupus erythematosus	1.88e-05	0.000416	CbGpPWpGaD
Everolimus—Dyspepsia—Prednisone—systemic lupus erythematosus	1.87e-05	0.000187	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—HLA-DRB1—systemic lupus erythematosus	1.87e-05	0.000414	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—IL6—systemic lupus erythematosus	1.87e-05	0.000414	CbGpPWpGaD
Everolimus—Nausea—Mycophenolate mofetil—systemic lupus erythematosus	1.86e-05	0.000186	CcSEcCtD
Everolimus—Chest pain—Methotrexate—systemic lupus erythematosus	1.85e-05	0.000186	CcSEcCtD
Everolimus—Arthralgia—Methotrexate—systemic lupus erythematosus	1.85e-05	0.000186	CcSEcCtD
Everolimus—Myalgia—Methotrexate—systemic lupus erythematosus	1.85e-05	0.000186	CcSEcCtD
Everolimus—Decreased appetite—Prednisone—systemic lupus erythematosus	1.85e-05	0.000185	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—TLR9—systemic lupus erythematosus	1.84e-05	0.000408	CbGpPWpGaD
Everolimus—Rash—Prednisolone—systemic lupus erythematosus	1.84e-05	0.000185	CcSEcCtD
Everolimus—Dermatitis—Prednisolone—systemic lupus erythematosus	1.84e-05	0.000184	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic lupus erythematosus	1.84e-05	0.000184	CcSEcCtD
Everolimus—MTOR—Immune System—CD40—systemic lupus erythematosus	1.84e-05	0.000407	CbGpPWpGaD
Everolimus—Diarrhoea—Methylprednisolone—systemic lupus erythematosus	1.84e-05	0.000184	CcSEcCtD
Everolimus—Fatigue—Prednisone—systemic lupus erythematosus	1.83e-05	0.000183	CcSEcCtD
Everolimus—Headache—Prednisolone—systemic lupus erythematosus	1.83e-05	0.000183	CcSEcCtD
Everolimus—Discomfort—Methotrexate—systemic lupus erythematosus	1.83e-05	0.000183	CcSEcCtD
Everolimus—Constipation—Prednisone—systemic lupus erythematosus	1.82e-05	0.000182	CcSEcCtD
Everolimus—Vomiting—Hydrocortisone—systemic lupus erythematosus	1.82e-05	0.000182	CcSEcCtD
Everolimus—MTOR—Immune System—HMGB1—systemic lupus erythematosus	1.81e-05	0.000401	CbGpPWpGaD
Everolimus—MTOR—Immune System—CTLA4—systemic lupus erythematosus	1.81e-05	0.000401	CbGpPWpGaD
Everolimus—Rash—Hydrocortisone—systemic lupus erythematosus	1.8e-05	0.00018	CcSEcCtD
Everolimus—MTOR—Innate Immune System—CD80—systemic lupus erythematosus	1.8e-05	0.000398	CbGpPWpGaD
Everolimus—Dermatitis—Hydrocortisone—systemic lupus erythematosus	1.8e-05	0.00018	CcSEcCtD
Everolimus—Headache—Hydrocortisone—systemic lupus erythematosus	1.79e-05	0.000179	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—P2RY12—systemic lupus erythematosus	1.79e-05	0.000395	CbGpPWpGaD
Everolimus—MTOR—Immune System—IFNA1—systemic lupus erythematosus	1.78e-05	0.000394	CbGpPWpGaD
Everolimus—Dizziness—Triamcinolone—systemic lupus erythematosus	1.78e-05	0.000178	CcSEcCtD
Everolimus—Dizziness—Methylprednisolone—systemic lupus erythematosus	1.77e-05	0.000178	CcSEcCtD
Everolimus—Infection—Methotrexate—systemic lupus erythematosus	1.76e-05	0.000177	CcSEcCtD
Everolimus—Feeling abnormal—Prednisone—systemic lupus erythematosus	1.75e-05	0.000175	CcSEcCtD
Everolimus—Asthenia—Dexamethasone—systemic lupus erythematosus	1.75e-05	0.000175	CcSEcCtD
Everolimus—Asthenia—Betamethasone—systemic lupus erythematosus	1.75e-05	0.000175	CcSEcCtD
Everolimus—Nervous system disorder—Methotrexate—systemic lupus erythematosus	1.74e-05	0.000174	CcSEcCtD
Everolimus—Thrombocytopenia—Methotrexate—systemic lupus erythematosus	1.74e-05	0.000174	CcSEcCtD
Everolimus—Gastrointestinal pain—Prednisone—systemic lupus erythematosus	1.74e-05	0.000174	CcSEcCtD
Everolimus—Nausea—Prednisolone—systemic lupus erythematosus	1.74e-05	0.000174	CcSEcCtD
Everolimus—MTOR—Immune System—RASGRP1—systemic lupus erythematosus	1.73e-05	0.000384	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD79A—systemic lupus erythematosus	1.73e-05	0.000382	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD80—systemic lupus erythematosus	1.73e-05	0.000382	CbGpPWpGaD
Everolimus—Pruritus—Betamethasone—systemic lupus erythematosus	1.73e-05	0.000173	CcSEcCtD
Everolimus—Pruritus—Dexamethasone—systemic lupus erythematosus	1.73e-05	0.000173	CcSEcCtD
Everolimus—Skin disorder—Methotrexate—systemic lupus erythematosus	1.72e-05	0.000173	CcSEcCtD
Everolimus—FKBP1A—Disease—CD80—systemic lupus erythematosus	1.72e-05	0.000381	CbGpPWpGaD
Everolimus—Hyperhidrosis—Methotrexate—systemic lupus erythematosus	1.72e-05	0.000172	CcSEcCtD
Everolimus—Vomiting—Triamcinolone—systemic lupus erythematosus	1.71e-05	0.000171	CcSEcCtD
Everolimus—Vomiting—Methylprednisolone—systemic lupus erythematosus	1.71e-05	0.000171	CcSEcCtD
Everolimus—Nausea—Hydrocortisone—systemic lupus erythematosus	1.7e-05	0.00017	CcSEcCtD
Everolimus—Rash—Triamcinolone—systemic lupus erythematosus	1.7e-05	0.00017	CcSEcCtD
Everolimus—Dermatitis—Triamcinolone—systemic lupus erythematosus	1.69e-05	0.00017	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—systemic lupus erythematosus	1.69e-05	0.000375	CbGpPWpGaD
Everolimus—Anorexia—Methotrexate—systemic lupus erythematosus	1.69e-05	0.00017	CcSEcCtD
Everolimus—Rash—Methylprednisolone—systemic lupus erythematosus	1.69e-05	0.000169	CcSEcCtD
Everolimus—Dermatitis—Methylprednisolone—systemic lupus erythematosus	1.69e-05	0.000169	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—HIST2H2AC—systemic lupus erythematosus	1.69e-05	0.000373	CbGpPWpGaD
Everolimus—MTOR—Disease—JUNB—systemic lupus erythematosus	1.68e-05	0.000373	CbGpPWpGaD
Everolimus—Headache—Triamcinolone—systemic lupus erythematosus	1.68e-05	0.000169	CcSEcCtD
Everolimus—MTOR—Immune System—PRL—systemic lupus erythematosus	1.68e-05	0.000372	CbGpPWpGaD
Everolimus—Headache—Methylprednisolone—systemic lupus erythematosus	1.68e-05	0.000168	CcSEcCtD
Everolimus—Abdominal pain—Prednisone—systemic lupus erythematosus	1.68e-05	0.000168	CcSEcCtD
Everolimus—Body temperature increased—Prednisone—systemic lupus erythematosus	1.68e-05	0.000168	CcSEcCtD
Everolimus—Diarrhoea—Betamethasone—systemic lupus erythematosus	1.67e-05	0.000167	CcSEcCtD
Everolimus—Diarrhoea—Dexamethasone—systemic lupus erythematosus	1.67e-05	0.000167	CcSEcCtD
Everolimus—Hypotension—Methotrexate—systemic lupus erythematosus	1.66e-05	0.000166	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—CSK—systemic lupus erythematosus	1.64e-05	0.000364	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Methotrexate—systemic lupus erythematosus	1.62e-05	0.000162	CcSEcCtD
Everolimus—Dizziness—Dexamethasone—systemic lupus erythematosus	1.61e-05	0.000162	CcSEcCtD
Everolimus—Dizziness—Betamethasone—systemic lupus erythematosus	1.61e-05	0.000162	CcSEcCtD
Everolimus—Insomnia—Methotrexate—systemic lupus erythematosus	1.61e-05	0.000161	CcSEcCtD
Everolimus—Nausea—Triamcinolone—systemic lupus erythematosus	1.6e-05	0.00016	CcSEcCtD
Everolimus—MTOR—Immune System—HLA-DQA1—systemic lupus erythematosus	1.59e-05	0.000353	CbGpPWpGaD
Everolimus—Paraesthesia—Methotrexate—systemic lupus erythematosus	1.59e-05	0.00016	CcSEcCtD
Everolimus—Nausea—Methylprednisolone—systemic lupus erythematosus	1.59e-05	0.00016	CcSEcCtD
Everolimus—Dyspnoea—Methotrexate—systemic lupus erythematosus	1.58e-05	0.000159	CcSEcCtD
Everolimus—Somnolence—Methotrexate—systemic lupus erythematosus	1.58e-05	0.000158	CcSEcCtD
Everolimus—Hypersensitivity—Prednisone—systemic lupus erythematosus	1.57e-05	0.000157	CcSEcCtD
Everolimus—Dyspepsia—Methotrexate—systemic lupus erythematosus	1.56e-05	0.000157	CcSEcCtD
Everolimus—MTOR—Disease—PRL—systemic lupus erythematosus	1.55e-05	0.000343	CbGpPWpGaD
Everolimus—Vomiting—Dexamethasone—systemic lupus erythematosus	1.55e-05	0.000155	CcSEcCtD
Everolimus—Vomiting—Betamethasone—systemic lupus erythematosus	1.55e-05	0.000155	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—JAK1—systemic lupus erythematosus	1.55e-05	0.000342	CbGpPWpGaD
Everolimus—Decreased appetite—Methotrexate—systemic lupus erythematosus	1.54e-05	0.000155	CcSEcCtD
Everolimus—Rash—Betamethasone—systemic lupus erythematosus	1.54e-05	0.000154	CcSEcCtD
Everolimus—Rash—Dexamethasone—systemic lupus erythematosus	1.54e-05	0.000154	CcSEcCtD
Everolimus—Dermatitis—Dexamethasone—systemic lupus erythematosus	1.54e-05	0.000154	CcSEcCtD
Everolimus—Dermatitis—Betamethasone—systemic lupus erythematosus	1.54e-05	0.000154	CcSEcCtD
Everolimus—Gastrointestinal disorder—Methotrexate—systemic lupus erythematosus	1.53e-05	0.000154	CcSEcCtD
Everolimus—Fatigue—Methotrexate—systemic lupus erythematosus	1.53e-05	0.000153	CcSEcCtD
Everolimus—Headache—Betamethasone—systemic lupus erythematosus	1.53e-05	0.000153	CcSEcCtD
Everolimus—Headache—Dexamethasone—systemic lupus erythematosus	1.53e-05	0.000153	CcSEcCtD
Everolimus—Asthenia—Prednisone—systemic lupus erythematosus	1.52e-05	0.000153	CcSEcCtD
Everolimus—MTOR—Innate Immune System—TYK2—systemic lupus erythematosus	1.52e-05	0.000336	CbGpPWpGaD
Everolimus—Pain—Methotrexate—systemic lupus erythematosus	1.52e-05	0.000152	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—NCF2—systemic lupus erythematosus	1.5e-05	0.000333	CbGpPWpGaD
Everolimus—Pruritus—Prednisone—systemic lupus erythematosus	1.5e-05	0.000151	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—LYN—systemic lupus erythematosus	1.49e-05	0.00033	CbGpPWpGaD
Everolimus—MTOR—Immune System—HLA-DQB1—systemic lupus erythematosus	1.49e-05	0.00033	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SH2B3—systemic lupus erythematosus	1.46e-05	0.000324	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCR5—systemic lupus erythematosus	1.46e-05	0.000324	CbGpPWpGaD
Everolimus—Feeling abnormal—Methotrexate—systemic lupus erythematosus	1.46e-05	0.000147	CcSEcCtD
Everolimus—Diarrhoea—Prednisone—systemic lupus erythematosus	1.45e-05	0.000146	CcSEcCtD
Everolimus—FKBP1A—Disease—TYK2—systemic lupus erythematosus	1.45e-05	0.000321	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Methotrexate—systemic lupus erythematosus	1.45e-05	0.000145	CcSEcCtD
Everolimus—Nausea—Betamethasone—systemic lupus erythematosus	1.45e-05	0.000145	CcSEcCtD
Everolimus—Nausea—Dexamethasone—systemic lupus erythematosus	1.45e-05	0.000145	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—IL2RA—systemic lupus erythematosus	1.44e-05	0.000319	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—C3—systemic lupus erythematosus	1.43e-05	0.000317	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NOS3—systemic lupus erythematosus	1.43e-05	0.000315	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL18—systemic lupus erythematosus	1.41e-05	0.000313	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD40LG—systemic lupus erythematosus	1.41e-05	0.000312	CbGpPWpGaD
Everolimus—Dizziness—Prednisone—systemic lupus erythematosus	1.4e-05	0.000141	CcSEcCtD
Everolimus—Abdominal pain—Methotrexate—systemic lupus erythematosus	1.4e-05	0.000141	CcSEcCtD
Everolimus—Body temperature increased—Methotrexate—systemic lupus erythematosus	1.4e-05	0.000141	CcSEcCtD
Everolimus—MTOR—Immune System—CD8A—systemic lupus erythematosus	1.39e-05	0.000308	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—IL6—systemic lupus erythematosus	1.39e-05	0.000307	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CD4—systemic lupus erythematosus	1.37e-05	0.000304	CbGpPWpGaD
Everolimus—Vomiting—Prednisone—systemic lupus erythematosus	1.35e-05	0.000135	CcSEcCtD
Everolimus—MTOR—Immune System—JAK1—systemic lupus erythematosus	1.34e-05	0.000298	CbGpPWpGaD
Everolimus—Rash—Prednisone—systemic lupus erythematosus	1.34e-05	0.000134	CcSEcCtD
Everolimus—Dermatitis—Prednisone—systemic lupus erythematosus	1.34e-05	0.000134	CcSEcCtD
Everolimus—Headache—Prednisone—systemic lupus erythematosus	1.33e-05	0.000133	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—CD4—systemic lupus erythematosus	1.32e-05	0.000292	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CD4—systemic lupus erythematosus	1.31e-05	0.000291	CbGpPWpGaD
Everolimus—Hypersensitivity—Methotrexate—systemic lupus erythematosus	1.31e-05	0.000131	CcSEcCtD
Everolimus—FKBP1A—Disease—PTGS2—systemic lupus erythematosus	1.3e-05	0.000289	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—IL6—systemic lupus erythematosus	1.3e-05	0.000288	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CDKN1B—systemic lupus erythematosus	1.29e-05	0.000286	CbGpPWpGaD
Everolimus—Asthenia—Methotrexate—systemic lupus erythematosus	1.27e-05	0.000128	CcSEcCtD
Everolimus—Nausea—Prednisone—systemic lupus erythematosus	1.26e-05	0.000126	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—F2—systemic lupus erythematosus	1.26e-05	0.000278	CbGpPWpGaD
Everolimus—Pruritus—Methotrexate—systemic lupus erythematosus	1.26e-05	0.000126	CcSEcCtD
Everolimus—MTOR—Immune System—IL2RA—systemic lupus erythematosus	1.26e-05	0.000278	CbGpPWpGaD
Everolimus—MTOR—Immune System—C3—systemic lupus erythematosus	1.24e-05	0.000276	CbGpPWpGaD
Everolimus—MTOR—Disease—JAK1—systemic lupus erythematosus	1.24e-05	0.000275	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CDKN1B—systemic lupus erythematosus	1.24e-05	0.000274	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CDKN1B—systemic lupus erythematosus	1.23e-05	0.000273	CbGpPWpGaD
Everolimus—Diarrhoea—Methotrexate—systemic lupus erythematosus	1.21e-05	0.000122	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—CD80—systemic lupus erythematosus	1.2e-05	0.000267	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCL12—systemic lupus erythematosus	1.2e-05	0.000266	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CDKN1A—systemic lupus erythematosus	1.19e-05	0.000264	CbGpPWpGaD
Everolimus—MTOR—Immune System—CRP—systemic lupus erythematosus	1.18e-05	0.000262	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—JUNB—systemic lupus erythematosus	1.18e-05	0.000261	CbGpPWpGaD
Everolimus—MTOR—Disease—CCR5—systemic lupus erythematosus	1.18e-05	0.00026	CbGpPWpGaD
Everolimus—Dizziness—Methotrexate—systemic lupus erythematosus	1.17e-05	0.000118	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—CDKN1A—systemic lupus erythematosus	1.14e-05	0.000253	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CDKN1A—systemic lupus erythematosus	1.14e-05	0.000252	CbGpPWpGaD
Everolimus—MTOR—Immune System—TLR4—systemic lupus erythematosus	1.14e-05	0.000251	CbGpPWpGaD
Everolimus—MTOR—Immune System—HLA-DRB1—systemic lupus erythematosus	1.13e-05	0.000251	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—EP300—systemic lupus erythematosus	1.13e-05	0.000251	CbGpPWpGaD
Everolimus—Vomiting—Methotrexate—systemic lupus erythematosus	1.13e-05	0.000113	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—RASGRP1—systemic lupus erythematosus	1.12e-05	0.000248	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCL2—systemic lupus erythematosus	1.12e-05	0.000248	CbGpPWpGaD
Everolimus—Rash—Methotrexate—systemic lupus erythematosus	1.12e-05	0.000112	CcSEcCtD
Everolimus—Dermatitis—Methotrexate—systemic lupus erythematosus	1.12e-05	0.000112	CcSEcCtD
Everolimus—Headache—Methotrexate—systemic lupus erythematosus	1.11e-05	0.000111	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—PRL—systemic lupus erythematosus	1.09e-05	0.000241	CbGpPWpGaD
Everolimus—FKBP1A—Disease—EP300—systemic lupus erythematosus	1.08e-05	0.00024	CbGpPWpGaD
Everolimus—Nausea—Methotrexate—systemic lupus erythematosus	1.05e-05	0.000106	CcSEcCtD
Everolimus—MTOR—Immune System—CD80—systemic lupus erythematosus	1.05e-05	0.000232	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TYK2—systemic lupus erythematosus	1.02e-05	0.000225	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NOS3—systemic lupus erythematosus	9.98e-06	0.000221	CbGpPWpGaD
Everolimus—MTOR—Disease—CD80—systemic lupus erythematosus	9.67e-06	0.000214	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TGFB1—systemic lupus erythematosus	9.42e-06	0.000209	CbGpPWpGaD
Everolimus—MTOR—Immune System—TYK2—systemic lupus erythematosus	8.85e-06	0.000196	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—JAK1—systemic lupus erythematosus	8.69e-06	0.000192	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CDKN1B—systemic lupus erythematosus	8.65e-06	0.000191	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL2—systemic lupus erythematosus	8.46e-06	0.000187	CbGpPWpGaD
Everolimus—MTOR—Immune System—IFNG—systemic lupus erythematosus	8.28e-06	0.000183	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCR5—systemic lupus erythematosus	8.24e-06	0.000182	CbGpPWpGaD
Everolimus—MTOR—Disease—TYK2—systemic lupus erythematosus	8.17e-06	0.000181	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL2RA—systemic lupus erythematosus	8.12e-06	0.00018	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—C3—systemic lupus erythematosus	8.05e-06	0.000178	CbGpPWpGaD
Everolimus—MTOR—Disease—NOS3—systemic lupus erythematosus	8.02e-06	0.000177	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MMP9—systemic lupus erythematosus	8.01e-06	0.000177	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD4—systemic lupus erythematosus	8e-06	0.000177	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CDKN1A—systemic lupus erythematosus	7.98e-06	0.000177	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EP300—systemic lupus erythematosus	7.59e-06	0.000168	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDKN1B—systemic lupus erythematosus	7.52e-06	0.000166	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6—systemic lupus erythematosus	7.43e-06	0.000164	CbGpPWpGaD
Everolimus—MTOR—Disease—CD4—systemic lupus erythematosus	7.39e-06	0.000163	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL2—systemic lupus erythematosus	7.36e-06	0.000163	CbGpPWpGaD
Everolimus—MTOR—Disease—PTGS2—systemic lupus erythematosus	7.33e-06	0.000162	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VEGFA—systemic lupus erythematosus	7.19e-06	0.000159	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6—systemic lupus erythematosus	7.1e-06	0.000157	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—F2—systemic lupus erythematosus	7.07e-06	0.000156	CbGpPWpGaD
Everolimus—MTOR—Disease—CDKN1B—systemic lupus erythematosus	6.94e-06	0.000154	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDKN1A—systemic lupus erythematosus	6.94e-06	0.000154	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CD80—systemic lupus erythematosus	6.77e-06	0.00015	CbGpPWpGaD
Everolimus—MTOR—Immune System—EP300—systemic lupus erythematosus	6.6e-06	0.000146	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TGFB1—systemic lupus erythematosus	6.6e-06	0.000146	CbGpPWpGaD
Everolimus—MTOR—Disease—CDKN1A—systemic lupus erythematosus	6.41e-06	0.000142	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCL2—systemic lupus erythematosus	6.3e-06	0.000139	CbGpPWpGaD
Everolimus—MTOR—Disease—EP300—systemic lupus erythematosus	6.1e-06	0.000135	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NAT2—systemic lupus erythematosus	5.85e-06	0.000129	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TYK2—systemic lupus erythematosus	5.72e-06	0.000127	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOS3—systemic lupus erythematosus	5.61e-06	0.000124	CbGpPWpGaD
Everolimus—MTOR—Disease—TGFB1—systemic lupus erythematosus	5.3e-06	0.000117	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6—systemic lupus erythematosus	4.97e-06	0.00011	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDKN1B—systemic lupus erythematosus	4.86e-06	0.000108	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL2—systemic lupus erythematosus	4.76e-06	0.000105	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MMP9—systemic lupus erythematosus	4.5e-06	9.97e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDKN1A—systemic lupus erythematosus	4.49e-06	9.93e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6—systemic lupus erythematosus	4.33e-06	9.57e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EP300—systemic lupus erythematosus	4.27e-06	9.45e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VEGFA—systemic lupus erythematosus	4.04e-06	8.95e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6—systemic lupus erythematosus	3.99e-06	8.84e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TGFB1—systemic lupus erythematosus	3.71e-06	8.22e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—RXRA—systemic lupus erythematosus	3.28e-06	7.26e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6—systemic lupus erythematosus	2.8e-06	6.19e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARG—systemic lupus erythematosus	2.07e-06	4.58e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALB—systemic lupus erythematosus	1.86e-06	4.12e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NOS3—systemic lupus erythematosus	1.78e-06	3.94e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS2—systemic lupus erythematosus	1.63e-06	3.6e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—EP300—systemic lupus erythematosus	1.35e-06	3e-05	CbGpPWpGaD
